CSLCSL Limited

CSL Stock Price, Valuation & Chart | CSL Limited

Compare

$173.64+4.53 (+2.68%)

At close · 25 Aug 2026, 06:10 am

Sector: Healthcare Industry: Biotechnology CSL intrinsic value Is CSL overvalued or undervalued Website

Overview Financials Dividends Ratios

CSL Historical price chart

CSL Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization83.16B

PE Ratio18.67

EPS9.3

Trading Volume1.20M

Today's High/Low174.75/170.32

Dividend Yield3.73

52 Week High/Low222.47/90.0

Shares Outstanding478.91M

CSL Financial Statement

CSL Analyst ratings

Neutral

Strong buy

Buy

Hold

Sell

Strong sell

Based on 17 analysts giving stock ratings to CSL in the past 3 months.

CSL Analysis & performance metrics

CSL Company profile

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom,…

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and CSL Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants. This segment…

CSL Management team

Name

Position

John A. G. Levy CPACFO

Interim Chief Financial Officer

William Mezzanotte M.D., M.P.H.

Executive Vice President & Head of Research and Development

Gregory Boss B.S., BS(Hons), J.D.

Executive Vice President of Legal & General Counsel

Joy Carolyn Linton B.Com., BComm, GAICD, Grad Dip AFI

Interim Executive Vice President of CSL Behring

Andy Schmeltz

Executive Vice President of CSL Behring Business Unit (Leave of Absence)

Mark Hill B.A., M.B.A.

Chief Digital Information Officer & Executive Vice President

Roanne Parry

Chief Human Resources Officer

Paul F. McKenzie Ph.D.CEO

MD, Chief Executive Officer & Executive Director

Name

Position

John A. G. Levy CPACFO

Interim Chief Financial Officer

William Mezzanotte M.D., M.P.H.

Executive Vice President & Head of Research and Development

Gregory Boss B.S., BS(Hons), J.D.

Executive Vice President of Legal & General Counsel

Joy Carolyn Linton B.Com., BComm, GAICD, Grad Dip AFI

Interim Executive Vice President of CSL Behring

Andy Schmeltz

Executive Vice President of CSL Behring Business Unit (Leave of Absence)

Mark Hill B.A., M.B.A.

Chief Digital Information Officer & Executive Vice President

Roanne Parry

Chief Human Resources Officer

Paul F. McKenzie Ph.D.CEO

MD, Chief Executive Officer & Executive Director

Management Team

John A. G. Levy CPACFO

Interim Chief Financial Officer

William Mezzanotte M.D., M.P.H.

Executive Vice President & Head of Research and Development

Gregory Boss B.S., BS(Hons), J.D.

Executive Vice President of Legal & General Counsel

Joy Carolyn Linton B.Com., BComm, GAICD, Grad Dip AFI

Interim Executive Vice President of CSL Behring

Andy Schmeltz

Executive Vice President of CSL Behring Business Unit (Leave of Absence)

Mark Hill B.A., M.B.A.

Chief Digital Information Officer & Executive Vice President

Roanne Parry

Chief Human Resources Officer

Paul F. McKenzie Ph.D.CEO

MD, Chief Executive Officer & Executive Director

Management

John A. G. Levy CPACFO

Interim Chief Financial Officer

William Mezzanotte M.D., M.P.H.

Executive Vice President & Head of Research and Development

Gregory Boss B.S., BS(Hons), J.D.

Executive Vice President of Legal & General Counsel

Joy Carolyn Linton B.Com., BComm, GAICD, Grad Dip AFI

Interim Executive Vice President of CSL Behring

Andy Schmeltz

Executive Vice President of CSL Behring Business Unit (Leave of Absence)

Mark Hill B.A., M.B.A.

Chief Digital Information Officer & Executive Vice President

Roanne Parry

Chief Human Resources Officer

Paul F. McKenzie Ph.D.CEO

MD, Chief Executive Officer & Executive Director

Total 8 executives

CSL Frequently asked questions

What is CSL Limited (CSL) Stock Price?

Current stock price of CSL Limited (CSL) stock is $173.64. The stock price is +2.68% higher in the session. The intraday range can be seen from this page. Volume of CSL Limited (CSL) stock is 1.20M.

Last updated at 25 Aug 2026, 06:10 am.

Why is the CSL Limited (CSL) stock price going up or down today?

The stock price of CSL Limited (CSL) can change with earnings, company news, and overall market sentiment. CSL Limited operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the CSL Limited stock expensive at its current price?

Whether CSL Limited looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for CSL on this page is 18.67. EPS on this page is 9.30. Compare those figures with peers and growth expectations before deciding if the current CSL Limited price is justified.

How has the stock price of CSL Limited (CSL) performed historically?

Historical performance for CSL Limited (CSL) is shown on the price chart on this page. Review multi-period moves alongside volume to see how CSL reacted to past earnings and market events.

Should I buy CSL Limited (CSL) stock, at this price?

Buying CSL Limited (CSL) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.